MediLink Therapeutics (Suzhou) Co., Ltd.

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
HER3Antibody–drug conjugate
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung CancerSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaNasopharyngeal CarcinomaEsophageal Cancer
Esophageal Squamous Cell Carcinoma

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Beruzatatug pelitecanPhase 2NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2026-11 · NCT06107686 · CT.gov ↗
What to watch
2027 (8)
January 2027 (2)
Tambotatug pelitecanPhase 1/2Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 2Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2027-01-31 · NCT07202364 · CT.gov ↗
What to watch
February 2027 (1)
Tambotatug pelitecanPhase 2Metastatic Castration-resistant Prostate Cancer (mCRPC)
Est. primary completion 2027-02 · NCT06241846 · CT.gov ↗
What to watch
April 2027 (1)
Tambotatug pelitecanPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-04-06 · NCT05434234 · CT.gov ↗
What to watch
July 2027 (1)
Beruzatatug pelitecanPhase 2Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-07-30 · NCT06439771 · CT.gov ↗
What to watch
December 2027 (3)
Tambotatug pelitecanPhase 3Small Cell Lung Cancer
Est. primary completion 2027-12-01 · NCT06612151 · CT.gov ↗
What to watch
Tambotatug pelitecanPhase 3Nasopharyngeal Carcinoma
Est. primary completion 2027-12-01 · NCT06629597 · CT.gov ↗
What to watch
Beruzatatug pelitecanPhase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2027-12-31 · NCT07461454 · CT.gov ↗
What to watch
2028 (6)
February 2028 (1)
Tambotatug pelitecanPhase 1/2Recurrent or Metastatic Nasopharyngeal Carcinoma
Est. primary completion 2028-02 · NCT07258979 · CT.gov ↗
What to watch
March 2028 (1)
Beruzatatug pelitecanPhase 1/2Advanced Solid Tumor
Est. primary completion 2028-03 · NCT07070232 · CT.gov ↗
What to watch
April 2028 (1)
Tambotatug pelitecanPhase 3Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-04-30 · NCT07487896 · CT.gov ↗
What to watch
August 2028 (1)
Beruzatatug pelitecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-08-31 · NCT07416994 · CT.gov ↗
What to watch
November 2028 (2)
Beruzatatug pelitecanPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2028-11 · NCT07111520 · CT.gov ↗
What to watch
Tambotatug pelitecanPhase 1/2Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Est. primary completion 2028-11 · NCT07407933 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Tambotatug pelitecanPhase 3Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2029-01 · NCT07803783 · CT.gov ↗
What to watch
June 2029 (1)
Tambotatug pelitecanPhase 3SCLC, Extensive Stage
Est. primary completion 2029-06 · NCT07739758 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 September 2026Topline resultYL201Phase 3 TAISHAN-302 (NCT06612151) met its overall survival primary endpoint at interim analysis
MediLink Therapeutics (reported by its collaborator Roche) · Source ↗

Financial reports

No financial reports recorded.